• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 29, 2025
Product Development

Bispecifics for I&I: Bypassing combination complexity

At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
Read More
BioCentury | Aug 6, 2020
Product Development

Aug. 5 Quick Takes: Strong quarterly sales of Horizon’s Tepezza, Global Blood’s Oxbryta; plus a setback for DBV and news from Point, Karuna, Evotec-Secarna, Red

Read More
BioCentury | Oct 25, 2018
Targets & Mechanisms

Blueprint for selectivity

Why Blueprint thinks its selective ALK2 inhibition is the best bet for treating FOP
Read More
BioCentury | Aug 23, 2018
Distillery Techniques

Assays and screens; imaging; drug properties

Read More
BioCentury | Apr 20, 2018
Clinical News

CHMP rebuffs AB Science’s masitinib in ALS

Read More
BioCentury | Apr 19, 2018
Company News

CHMP rebuffs AB Science’s masitinib in ALS

Read More
BioCentury | Nov 10, 2016
Tools & Techniques

A different horse in the race

How modified peptide nucleic acids could be new in vivo gene editing tools
Read More
BioCentury | Nov 20, 2014
Distillery Therapeutics

Indication: Cardiovascular disease

Read More
BioCentury | Jan 22, 2009
Targets & Mechanisms

A niche play for stem cells

Read More
BioCentury | Jan 22, 2009
Distillery Therapeutics

Indication: Cancer

Read More
Items per page:
1 - 10 of 11